MAP
MRTX

Moody Aldrich Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Moody Aldrich Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18,760
Closed -$1.93M – 144
2019
Q2 		$1.93M Buy
18,760
+5,619
+43% +$437K 0.49% 76
2019
Q1 		$963K Buy
+13,141
New +$894K 0.27% 87

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Moody Aldrich Partners's MRTX Position: Q3 2019 in Review

Moody Aldrich Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2019, closing a stake of 18,760 shares — an estimated $1.93M sold.

Moody Aldrich Partners first reported a position in MRTX in Q1 2019 and held it in 2 quarters. The position peaked at $1.93M in Q2 2019. 177 funds tracked by Wall St. Rank hold MRTX as of Q3 2019.

  • Moody Aldrich Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Moody Aldrich Partners sold 18,760 Mirati Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $1.93M.
  • Moody Aldrich Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 2 quarters.
  • Moody Aldrich Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $1.93M in Q2 2019.
  • 177 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Moody Aldrich Partners's 13F filing for Q3 2019, filed 12 Nov 2019.